UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer

The lancet oncology, 2015-09, Vol.16 (9), p.e447-e459

2015

Volltextzugriff (PDF)

A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma

Clinical cancer research, 2019-05, Vol.25 (9), p.2708-2716

2019

Volltextzugriff (PDF)

Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies

Journal of clinical oncology, 2005-06, Vol.23 (18), p.4152-4161

2005

Volltextzugriff (PDF)

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

Clinical cancer research, 2007-10, Vol.13 (20), p.6187-6194

2007

Volltextzugriff (PDF)

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

Clinical cancer research, 2008-10, Vol.14 (20), p.6663-6673

2008

Volltextzugriff (PDF)

A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study

European urology open science (Online), 2022-04, Vol.38, p.17-24

2022

Volltextzugriff (PDF)

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin

Clinical cancer research, 2010-07, Vol.16 (14), p.3795-3804

2010

Volltextzugriff (PDF)

Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms

JTO clinical and research reports, 2020-11, Vol.1 (4), p.100093-100093, Article 100093

2020

Volltextzugriff (PDF)

Tumor necrosis factor receptor‐2 signaling pathways promote survival of cancer stem‐like CD133+ cells in clear cell renal carcinoma

FASEB bioAdvances, 2020-02, Vol.2 (2), p.126-144

2020

Volltextzugriff (PDF)

Liquid biopsies come of age: towards implementation of circulating tumour DNA

Nature reviews. Cancer, 2017-04, Vol.17 (4), p.223-238

2017

Volltextzugriff (PDF)

Implementation and yield of upfront genomic profiling in a clinical prostate cancer diagnostic pathway

BJU international, 2023-11, Vol.132 (5), p.499-501

2023

Volltextzugriff (PDF)

Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA

Genome research, 2022-02, Vol.32 (2), p.215-227

2022

Volltextzugriff (PDF)

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers

Journal of clinical oncology, 2017-06, Vol.35 (16), p.1778-1785

2017

Volltextzugriff (PDF)

Using prognosis to guide early detection and treatment selection in non‐metastatic prostate cancer

BJU international, 2019-04, Vol.123 (4), p.562-563

2019

Volltextzugriff (PDF)

A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS5105-TPS5105

2023

Volltextzugriff (PDF)

PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.123-123

2024

Volltextzugriff (PDF)

ASCERTAIN: An open-label, randomized, phase 1, window-of-opportunity study to investigate the biological effects of AZD5305 and darolutamide alone or in combination in men with prostate cancer eligible for radical prostatectomy

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.TPS356-TPS356

2024

Volltextzugriff (PDF)

A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2691-TPS2691

2022

Volltextzugriff (PDF)

A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors

Clinical cancer research, 2011-03, Vol.17 (6), p.1561-1570

2011

Volltextzugriff (PDF)

A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma

Investigational new drugs, 2012-02, Vol.30 (1), p.341-349

2012

Volltextzugriff (PDF)

The role of chemotherapy and new targeted agents in the management of primary prostate cancer

Journal of clinical urology, 2016-12, Vol.9 (2_suppl), p.30-37

2016

Volltextzugriff (PDF)

Abstract A021: Pre and post treatment transcriptomic analysis provide new insights on the mechanisms underlying the efficacy of PARPi and Androgen blockage in prostate cancer

Cancer research (Chicago, Ill.), 2024-01, Vol.84 (1_Supplement), p.A021-A021

2024

Volltextzugriff (PDF)

Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells

Cancer research (Chicago, Ill.), 2009-03, Vol.69 (5), p.1966-1975

2009

Volltextzugriff (PDF)

A novel Atg5-shRNA mouse model enables temporal control of Autophagy in vivo

Autophagy, 2018-07, Vol.14 (7), p.1256-1266

2018

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(59)
Buchkapitel
(1)

Sprache

Englisch
(60)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer

A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma

Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin

Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms

Tumor necrosis factor receptor‐2 signaling pathways promote survival of cancer stem‐like CD133+ cells in clear cell renal carcinoma

Liquid biopsies come of age: towards implementation of circulating tumour DNA

Enhanced detection of circulating tumor DNA by fragment size analysis

Implementation and yield of upfront genomic profiling in a clinical prostate cancer diagnostic pathway

Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers

Using prognosis to guide early detection and treatment selection in non‐metastatic prostate cancer

A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC)

PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results

ASCERTAIN: An open-label, randomized, phase 1, window-of-opportunity study to investigate the biological effects of AZD5305 and darolutamide alone or in combination in men with prostate cancer eligible for radical prostatectomy

A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies

A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors

A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma

The role of chemotherapy and new targeted agents in the management of primary prostate cancer

Abstract A021: Pre and post treatment transcriptomic analysis provide new insights on the mechanisms underlying the efficacy of PARPi and Androgen blockage in prostate cancer

Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells

A novel Atg5-shRNA mouse model enables temporal control of Autophagy in vivo

Suchergebnisse filtern